GGrantIndex
← Leaderboards

Ali J. Marian

Baylor College Of Medicine

$17,600,929
Attributed
$17,600,929
Total exposure
9
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.6M · FY200525
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$17,600,929 · 9

By mechanism

R01$15,769,378 · 5
P50$739,852 · 1
R34$569,449 · 1
R21$338,250 · 1
S10$184,000 · 1

Top collaborators

No co-investigators on record.

Most similar at Baylor College Of Medicine

Same institution · by research overlap

Others in their field

Top investigators on “Phenotype

Research focus

PhenotypeCardiac MyocytesMutationHeart FailureHeartMolecularGeneticMouse ModelProteinsCardiacPathogenesisGenesGene ExpressionFibrosisMediatingArrhythmiaCellsCell TypePathway InteractionsPrematurePreventMapsCardiomyopathiesPrevention

Grant awards (41)

Mechanisms and Therapeutic Targeting of DNA Damage in Dilated Cardiomyopathy Caused by LMNA Mutations$580,531
R01 · FY2025 · HL · contact PI
Cytosolic DNA is the Link Between Genomic Instability and Cardiovascular Aging$575,947
R01 · FY2025 · AG · contact PI
Cytosolic DNA is the Link Between Genomic Instability and Cardiovascular Aging$587,703
R01 · FY2024 · AG · contact PI
Mechanisms and Therapeutic Targeting of DNA Damage in Dilated Cardiomyopathy Caused by LMNA Mutations$580,531
R01 · FY2024 · HL · contact PI
Cytosolic DNA is the Link Between Genomic Instability and Cardiovascular Aging$615,703
R01 · FY2023 · AG · contact PI
Cell type-Specific Therapeutic Targeting of canonical WNT Pathway in Arrhythmogenic Cardiomyopathy$493,640
R01 · FY2023 · HL · contact PI
Mechanisms and Therapeutic Targeting of DNA Damage in Dilated Cardiomyopathy Caused by LMNA Mutations$483,887
R01 · FY2023 · HL · contact PI
Cell type-Specific Therapeutic Targeting of canonical WNT Pathway in Arrhythmogenic Cardiomyopathy$493,640
R01 · FY2022 · HL · contact PI
Mechanisms and Therapeutic Targeting of DNA Damage in Dilated Cardiomyopathy Caused by LMNA Mutations$483,887
R01 · FY2022 · HL · contact PI
Cell type-Specific Therapeutic Targeting of canonical WNT Pathway in Arrhythmogenic Cardiomyopathy$493,640
R01 · FY2021 · HL · contact PI
Mechanisms and Therapeutic Targeting of DNA Damage in Dilated Cardiomyopathy Caused by LMNA Mutations$483,887
R01 · FY2021 · HL · contact PI
Cell type-Specific Therapeutic Targeting of canonical WNT Pathway in Arrhythmogenic Cardiomyopathy$491,003
R01 · FY2020 · HL · contact PI
Mechanisms and Therapeutic Targeting of DNA Damage in Dilated Cardiomyopathy Caused by LMNA Mutations$483,370
R01 · FY2020 · HL · contact PI
Pathogenic Role of Selected Cardiac Myocyte- and Fibroblast-Specific Epigenetic Changes in Laminopathies$567,052
R01 · FY2019 · HL · contact PI
Pathogenic Role of Selected Cardiac Myocyte- and Fibroblast-Specific Epigenetic Changes in Laminopathies$567,052
R01 · FY2018 · HL · contact PI
Pathogenic Role of Selected Cardiac Myocyte- and Fibroblast-Specific Epigenetic Changes in Laminopathies$567,052
R01 · FY2017 · HL · contact PI
Canonical Wnt Signaling in Pathogenesis and Rescue of ARVC$380,000
R01 · FY2017 · HL · contact PI
Pathogenic Role of Selected Cardiac Myocyte- and Fibroblast-Specific Epigenetic Changes in Laminopathies$594,052
R01 · FY2016 · HL · contact PI
Canonical Wnt Signaling in Pathogenesis and Rescue of ARVC$380,000
R01 · FY2016 · HL · contact PI
Canonical Wnt Signaling in Pathogenesis and Rescue of ARVC$374,300
R01 · FY2015 · HL · contact PI
Cardiovascular Ultrasonography Unit$184,000
S10 · FY2015 · OD · contact PI
Canonical Wnt Signaling in Pathogenesis and Rescue of ARVC$380,000
R01 · FY2014 · HL · contact PI
Hypertrophy Regression with N-Acetylcysteine in Hypertrophic Cardiomyopathy$191,017
R34 · FY2014 · HL · contact PI
Hypertrophy Regression with N-Acetylcysteine in Hypertrophic Cardiomyopathy$184,817
R34 · FY2013 · HL · contact PI
Canonical Wnt Signaling in Pathogenesis and Rescue of ARVC Phenotype$371,250
R01 · FY2012 · HL · contact PI
Hypertrophy Regression with N-Acetylcysteine in Hypertrophic Cardiomyopathy$193,615
R34 · FY2012 · HL · contact PI
Mouse Models of Non-Syndromic Cardiac Progeria$153,750
R21 · FY2012 · AG · contact PI
Canonical Wnt Signaling in Pathogenesis and Rescue of ARVC Phenotype$375,000
R01 · FY2011 · HL · contact PI
Mouse Models of Non-Syndromic Cardiac Progeria$184,500
R21 · FY2011 · AG · contact PI
Canonical Wnt Signaling in Pathogenesis and Rescue of ARVC Phenotype$375,000
R01 · FY2010 · HL · contact PI
Canonical Wnt Signaling in Pathogenesis and Rescue of ARVC Phenotype$375,000
R01 · FY2009 · HL · contact PI
Canonical Wnt Signaling in Pathogenesis and Rescue of ARVC Phenotype$372,500
R01 · FY2008 · HL · contact PI
Modifier Genes of Familial Hypertrophic Cardiomyopathy$625,539
R01 · FY2005 · HL
Modifier Genes of Familial Hypertrophic Cardiomyopathy$625,539
R01 · FY2004 · HL
Modifier Genes of Familial Hypertrophic Cardiomyopathy$625,539
R01 · FY2003 · HL
Modifier Genes of Familial Hypertrophic Cardiomyopathy$655,489
R01 · FY2002 · HL
Prevention, treatment, pathogenesis of hypertrophic cardiomyopathy$184,963
P50 · FY2002 · HL
Prevention, treatment, pathogenesis of hypertrophic cardiomyopathy$184,963
P50 · FY2002 · HL
Modifier Genes of Familial Hypertrophic Cardiomyopathy$711,645
R01 · FY2001 · HL
Prevention, treatment, pathogenesis of hypertrophic cardiomyopathy$184,963
P50 · FY2001 · HL
Prevention, treatment, pathogenesis of hypertrophic cardiomyopathy$184,963
P50 · FY2000 · HL